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Summary
Background.— Optical coherence tomography is a high-resolution imaging technology that
allows in vivo assessment of neointimal hyperplasia and strut coverage after coronary stenting.
Aim.— Assessment of spatial distribution of healing, 6 months after zotarolimus-eluting stenthyperplasia;
Zotarolimus-eluting
stent
implantation.
Methods.— Forty-two zotarolimus-eluting stents were monitored by optical coherence tomog-
raphy 6 months after implantation. Mean neointimal strut coverage thickness and percentage of
neointimal hyperplasia were measured every millimetre. Non-covered strut ratios were assessed
on each slice. In addition, the spatial distribution of neointimal hyperplasia and strut coverage
were analysed longitudinally on ﬁve stent segments and axially on each slice.
Abbreviations: DES, drug-eluting stent; NIH, neointimal hyperplasia; OCT, optical coherence tomography; PES, paclitaxel-eluting
stent; QCA, quantitative coronary angiography; SES, sirolimus-eluting stent; ZES, zotarolimus-eluting stent.
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Results.— There were no clinical events at 6 months under dual antiplatelet therapy. The
optical coherence tomography analysis showed a mean neointimal hyperplasia thickness of
333± 147m and neointimal hyperplasia obstruction of 36.1± 12.3%. The percentage of cov-
ered struts at 6 months was very high (98.9%). Only 6/745 slices analysed (0.8%) had non-covered
strut ratios exceeding 30%. There was no signiﬁcant heterogeneity in either longitudinal or axial
neointimal hyperplasia distribution. No thrombi were observed.
Conclusion.— This optical coherence tomography study found relatively constant neointimal
hyperplasia thickness, regardless of the zotarolimus-eluting stent length or diameter. This spa-
tially homogeneous neointimal hyperplasia was associated with near-total coverage of all struts,
6 months after implantation.
© 2011 Elsevier Masson SAS. All rights reserved.
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Résumé
Contexte.— L’imagerie par cohérence optique (OCT) est une imagerie de haute résolution per-
mettant l’analyse in vivo de l’hyperplasie néo-intimale et de la couverture des mailles des
stents.
Objectif.— Analyse quantitative de la couverture néo-intimale de stents au zotarolimus à six
mois et de sa distribution spatiale.
Méthode.— Quarante-deux stents au zotarolimus ont été contrôlé par OCT six mois après leur
implantation. L’épaisseur moyenne de la couverture néo-intimale des mailles et le pourcentage
d’hyperplasie néo-intimale ont été mesurés tous les millimètres. Sur chaque coupe, le ratio de
mailles non couvertes est mesuré. La distribution spatiale de l’hyperplasie néo-intimale et de
la couverture du stent est analysée longitudinalement sur cinq segments du stent et axialement
sur chaque coupe.
Résultats.— Il n’y a pas eu d’évènements cliniques à six mois sous double anti-agrégation
plaquettaire. L’analyse OCT retrouve une épaisseur moyenne d’hyperplasie néo-intimale de
333± 147m et une obstruction néo-intimale de 36,1± 12,3 %. Le pourcentage de mailles cou-
vertes à six mois est élevé de 98,9 %. Seulement six coupes sur les 745 analysées (0,8 %) ont
un ratio de mailles non couvertes/couvertes de plus de 30%. La distribution de l’hyperplasie
néo-intimale est homogène en axial et en longitudinal. Aucun thrombus n’a été visualisé.
Conclusion.— Cette analyse OCT retrouve une épaisseur d’hyperplasie néo-intimale relative-
ment homogène dans le stent, quelle que soit sa longueur ou son diamètre. Cette homogénéité
d’hyperplasie néo-intimale est associée à une couverture quasi totale des mailles six mois après
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ackground
andomised studies have shown that DESs signiﬁcantly
educe clinical restenosis rates compared with bare-metal
tents [1—4]. This beneﬁt is due to inhibition of intimal neo-
roliferation [5]. Animal and autopsy studies, however, have
hown this effect to be associated with delayed or deﬁcient
rterial healing. It is therefore advisable to continue dual
ntiplatelet therapy beyond the ﬁrst month post stenting,
n order to avoid late intrastent thrombosis [6]. In a series
f 8000 DESs, Wenaweser et al. reported a consistent 0.6%
nnual late thrombosis rate over the ﬁrst 4 years post stent-
ng [7].
Intrastent thrombosis is a multifactorial phenomenon
8], but one signiﬁcant factor is failure of stent—strut
e-endothelialization [9]. Post-mortem studies of stented
ubjects [10] have reported deﬁcient re-endothelialization
o be more frequently associated with late intrastent throm-
osis than with other causes of death [11,12].
OCT is a high-resolution (around 10microns) imaging
echnology that is particularly well adapted for the study
f the most superﬁcial layers of the vessel wall and for
t
O
s
c
Ds droits réservés.
trut-by-strut stent analysis. Several recent studies have
ocused on OCT analysis of neointimal coverage in bare-
etal and ﬁrst-generation DESs [13—16].
The present study used OCT to quantify and analyse the
patial distribution of NIH and strut coverage, 6 months after
ES implantation.
ethods
tudy population and methods
etween October 2006 and September 2007, 25 patients
21 men, four women) gave consent and were included
n this prospective, observational study. These 25 patients
ere selected from the 220 patients who underwent ZES
mplantation in our centre during the study period, using
he following inclusion criteria: consent and feasibility of
CT. Exclusion criteria were left main coronary artery steno-
is, bypass lesion, ostial stenosis, renal insufﬁciency, acute
oronary syndrome, stent overlapping, contraindication for
ES and OCT limitations. OCT limitations were tortuous and
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calciﬁed vessels, proximal lesion or large coronary diame-
ter (> 3.5mm) preventing the good saline ﬂush downstream
of an occlusion balloon that is necessary for image quality.
The 25 patients underwent native coronary stenting, using a
total of 42 ZESs. Angiographic analyses were done at base-
line and after angioplasty. The angiograms were evaluated
by a QCA system (QuantCor, CASS II, Siemens, Erlangen, Ger-
many). An angiographic control with OCT was scheduled at 6
months post stenting. Restenosis was deﬁned as > 50% lumen
narrowing on QCA.
Optical coherence tomography procedure
Optical coherence tomography at 6 months post stenting
immediately followed the control angiography. A 6F catheter
was used to inject 30UI/kg of unfractionated heparin intra-
arterially. A 0.014-inch guide was introduced into the vessel
and positioned distally to the stent. A HeliosTM coaxial occlu-
sion balloon catheter (LightLab Imaging, Westford, MA, USA)
was then introduced along the guide across the vessel until
the balloon marker was at the distal extremity of the stent.
The guide was then withdrawn and replaced by a 1.4F optic
ﬁbre, connected up to the OCT system (M2 version, LightLab
Imaging, Westford, MA, USA) and inserted through the bal-
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Figure 1. Stent analysis on optical coherence tomography millimetric im
malapposed; D. facing collateral); (b) quantitative analysis (neointimal h
strut [red arrows]); (c) longitudinal analysis in ﬁve segments of equal lengt
D2: distal).149
oon until distal to the stent. The occlusion balloon was then
ithdrawn until proximal to the DES and inﬂated to between
.4 and 0.7 atm. Physiological saline was then injected
ownstream of the occlusion balloon via its coaxial catheter;
0mL were injected during each pullback. OCT gives a clear
mage once the lumen is sufﬁciently transparent. Automatic
ight-source pullback then began (1mm/s, with 15 image/s
cquisitions). A 30-mm DICOM-format video recording of the
rtery was made, including the stented segment. The bal-
oon was then deﬂated and the saline injection stopped.
everal pullbacks were sometimes needed for analysis of the
ongest stents. Pullback was repeated until perfect visual-
zation of the whole length of all stents was obtained.
ptical coherence tomography analysis
ptical coherence tomography images were selected from
he DICOM pullback recordings every millimetre (every 15
mages) over the entire stented segment and were analysed
y two independent operators (Fig. 1).
Each strut was classiﬁed into one of four categories:
well apposed to vessel wall with apparent neointimal cov-
erage (A);
ages: (a) qualitative strut analysis (A. covered; B. non-covered; C.
yperplasia area [green]; lumen area [red]; coverage thickness per
h (P2: proximal; P1: proximal-medial; M: medial; D1: distal-medial;
1 G. Souteyrand et al.
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Table 1 Population characteristics.
Characteristic
Patients 25 (100)
Age (years) 59.7± 10.1
Men 21 (84)
Cardiovascular risk factors
Tobacco smoke 14 (56)
Diabetes mellitus 7 (28)
High blood pressure 12 (48)
High blood cholesterol 15 (60)
Obesity 7 (28)
Heredity 9 (36)
History of coronary artery disease 2 (8)
Context of stable angina 25 (100)
Number of stents per patient 1.68± 0.56
Lesions 42 (100)
Target vessel
LAD 19 (45)
LCX 7 (17)
RCA 16 (38)
Lesion type (ACC/AHA)
A 6 (14)
B1 24 (57)
B2 12 (29)
C 0 (0)
Reference lumen diameter (mm) 2.96± 0.33
Minimum lumen diameter (mm) 0.67± 0.29
Diameter stenosis (%) 77.5± 8.9
Lesion length (mm) 14.45± 5.68
Zotarolimus stents used 42 (100)
Stent diameter (mm) 3.01± 0.34
Stent length (mm) 18.40± 6.30
Maximum inﬂation pressure (atm) 14.0± 2.4
Direct stenting 34 (81)
Post dilatation 7 (17)
Final success 42 (100)
Post angioplasty QCA data
Reference vessel diameter (mm) 2.99± 0.33
Minimum lumen diameter (mm) 2.92± 0.35
Diameter stenosis (%) 2.3± 3.4
Acute gain (mm) 2.25± 0.34
ACC: American College of Cardiology; AHA: American Heart
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well apposed to vessel wall but without neointimal cover-
age (non-coverage being deﬁned as absence of any visible
structure between lumen and vessel on OCT, with strut
reﬂection) (B);
malapposed to vessel wall without neointimal cover-
age (malapposition being deﬁned as > 110m distance
between strut reﬂection and vessel wall, corresponding
to OCT axial resolution + ZES strut thickness) (C);
located at a bifurcation (D).
Struts in class A were assigned their measured coverage
hickness in micrometer; otherwise, the assigned value was
.
Strut information was used to produce cross-sectional
riteria:
overall NIH quantiﬁcation, in terms of mean strut cover-
age thickness;
cross-sectional heterogeneity of NIH, in terms of the coef-
ﬁcient of variation (i.e. standard deviation divided by
mean) of strut coverage thickness;
global coverage deﬁciency, in terms of the non-covered
strut ratio, deﬁned as the proportion of struts in cate-
gories B, C and D.
NIH quantiﬁcation was also assessed in each slice from
oth lumen area (in millimetre square) and stent area (in
illimetre square), computing percentage NIH area, deﬁned
s NIH obstruction (%) = (stent area—lumen area)/SA*100.
Longitudinal NIH distribution was assessed using the
ean values for each of the aforementioned criteria on
ach of ﬁve predeﬁned longitudinal stent segments of equal
ength (proximal, proximal-medial, medial, distal-medial
nd distal).
tatistical analysis
ategorical variables are described as frequencies and
ercentages. Continuous variables are displayed as
eans± standard deviations. Longitudinal NIH distribution
sed a mixed linear model to account for segment nesting
ithin a given stent. Longitudinal effect (i.e. possible
ongitudinal NIH distribution heterogeneity) was assessed
hrough a global F statistic, completed, as appropriate, by
ost-hoc multiple comparison of the ﬁve predeﬁned stent
egments.
The analyses were performed using SAS 9.2 software (SAS
nstitute, Inc., Cary, NC, USA).
esults
opulation characteristics
opulation characteristics are given in Table 1. The 25
ncluded patients (mean age, 59.7± 10.1 years) were
tented at severe coronary stenosis sites (77.5± 8.9% diam-
ter stenosis on QCA). Minimum lesion diameter and length
ere 0.67± 0.29mm and 14.45± 5.68mm, respectively,
ith a reference diameter of 2.99± 0.33mm.
A total of 42 ZESs (1.68 per patient) were implanted
n de novo lesions, with good initial angiographic results.
tent diameter ranged from 2.5 to 4.0mm (mean,
.01± 0.34mm) and length ranged from 8 to 30mm (mean,
t
(
r
wAssociation; LAD: left anterior descending; LCX: left circumﬂex;
QCA: quantitative coronary angiography; RAD: right anterior
descending. Data are number (%) or mean± standard deviation.
8.40± 6.30mm). Implantation used a mean balloon pres-
ure of 14.0± 2.4 atm, usually without predilatation (81%).
ean acute diameter gain was 2.25± 0.34mm.
linical and angiographic follow-up
here were no complications secondary to angioplasty dur-
ng the 6-month follow-up period under dual antiplatelet
herapy or during the OCT procedure.
At 6 months, there were no intrastent binary restenoses
angiographic diameter stenosis > 50%) requiring further
evascularization. Mean restenosis diameter was 20.2± 8.7%
ith a mean late-loss of 0.52± 0.30mm on QCA.
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Optical coherence tomography analysis
Optical coherence tomography was feasible in all 25 patients
and 69 pullbacks were performed to analyse the 42 stents
(1.64 per stent). In all, 745mm of stent were studied, and
10 169 struts were visualized. Strut coverage thickness was
assessed by two independent operators. Concordance on
quantitative measurements was virtually perfect, with an
intraclass correlation coefﬁcient of 0.99. The value sub-
mitted for analysis was the mean of the two observers’
estimates. Strut coverage was likewise classiﬁed in the
four exclusive categories by the two independent observers,
Table 2 Results of optical coherence tomography
analysis.
Variable
QCA data
Reference lumen diameter
(mm)
3.00± 0.33
Minimum lumen diameter (mm) 2.40± 0.46
Diameter stenosis (%) 20.2± 8.7
Late-loss (mm) 0.52± 0.30
OCT data
Stents (n = 42)
Lumen area (mm2) 5.46± 2.17
Stent area (mm2) 8.31± 2.15
NIH area (mm2) 2.85± 0.82
NIH obstruction (%) 36.1± 12.3
Lumen diameter (mm) 2.57± 0.52
Stent diameter (mm) 3.22± 0.41
NIH thickness (mm) 0.65± 0.23
Cross sections (n = 745)
Number of cross sections per
stent
17.7± 5.7
Cross sections with all
covered struts
699 (93.8)
Cross sections with
non-covered struts
23 (3.1)
Cross sections with
malapposed struts
11 (1.5)
Cross sections with struts
facing a collateral branch
12 (1.6)
Cross sections with thrombus 0 (0)
Cross sections with
non-covered strut
ratio > 0.3
6 (0.8)
Struts (n = 10169)
Number of struts per stent 242.1± 92
Covered struts 10058 (98.9)
Non-covered struts 46 (0.5)
Malapposed struts 47 (0.5)
Collateral struts 18 (0.2)
Coverage thickness per strut
(m)
333± 147
NIH: neointimal hyperplasia; OCT: optical coherence tomogra-
phy; QCA: quantitative coronary angiography. Data are number
(%) or mean± standard deviation.
again with virtually perfect agreement (kappa = 0.99). In
case of disagreement, the category to be adopted for anal-
ysis was determined by a third observer. Results are shown
in Table 2.
Neointimal hyperplasia
Mean stent area was 8.31± 2.15 m2 and mean lumen area
was 5.46± 2.17 mm2. Mean NIH area was 2.85± 0.82 mm2,
with a percentage obstruction of 36.1± 12.3%. Considering
lumen area and stent area as disks, with diameters cal-
culated as diameter = 2*
√
(area/), mean stent diameter,
lumen diameter and NIH thickness were 3.22± 0.41mm,
2.57± 0.52mm and 0.65± 0.23mm, respectively. Mean cov-
erage thickness measured on each strut (n = 10,169) was
333± 147m for 42 ZESs.
Neointimal strut coverage
The incidence of non-covered struts was very low at 6
months (111/10,169; non-covered strut ratio = 1.1%). Only
65 struts were observed to be remote from the coronary
wall because of malapposition (0.5%) or a collateral branch
(0.2%). On most slices, all struts were covered (699/745,
93.8%). No thrombi were observed in any of the 42 stents.
The rate of cross sections with a non-covered strut
ratio > 0.3 was very low (6/745, 0.8%). On the 745 slices,
a converse relation was also found between non-covered
strut ratio and strut coverage thickness or NIH percentage
obstruction (Fig. 2).
Spatial distribution of neointimal hyperplasia
Fig. 3 shows mean stent area, lumen area, NIH area, strut
coverage thicknesses, NIH obstruction and non-covered strut
ratio on the 745 slices and in each segment. There were
no signiﬁcant differences in longitudinal distribution with
regard to any of the criteria studied (p > 0.05).
Figure 2. Relationship between strut coverage thickness (m),
neointimal hyperplasia (NIH) obstruction (%) and non-covered strut
ratio, studied on 745 optical coherence tomography slices (699
slices with all struts covered; 28 slices with non-covered strut [NCS]
ratio < 0.15; 12 slices with NCS ratio between 0.15 and 0.30; six
slices with NCS ratio > 0.30).
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Mean cross-sectional NIH heterogeneity was very low
0.375± 0.107). No longitudinal effect was found on this cri-
erion (p = 0.662), suggesting a high level of longitudinal NIH
omogeneity.
iscussion
ptical coherence tomography is a particularly effective,
igh-resolution, imaging technique for analysing the more
uperﬁcial coronary layers and controlling stenting. The
resent study conﬁrms the feasibility of the technique in
elected lesions and the good reproducibility of its qualita-
ive and quantitative analysis of neointimal stent coverage.
ll 42 stents initially selected for control were analysed.
N
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igure 3. Spatial distribution of neointimal hyperplasia (NIH) and stru
n = 42), from quantitative optical coherence tomography analysis. A. M
45 slices; mean areas in ﬁve longitudinal stent segments (P2: proximal;
ean strut coverage thickness (m) in all cross sections and in ﬁve lon
ercentage obstruction (points). C. Mean non-covered strut ratio in all cG. Souteyrand et al.
Previous angiographic ﬁndings showed greater late-loss
fter implantation of a ZES compared with a ﬁrst-generation
ES (SES or PES). In 11 randomised trials, Pocock et al.
eported a late-loss of less than 0.21mm with SESs, between
.30 and 0.49mm with PESs, between 0.60 and 0.61mm with
ESs, and between 0.80 and 1.06mm with bare-metal stents
17].
Comparative OCT studies have conﬁrmed greater NIH
fter ZES implantation. Kim et al. [18] observed a mean NIH
hickness of 251.2 vs 85.5m (p < 0.001) and a percentage
IH area of 27.9 vs 11.2% (p < 0.001) at 9 months with ZESs
nd SESs, respectively. In a previous study [19], we found
signiﬁcant difference between ZESs and PESs: mean strut
overage thickness 333 vs 154m (p < 0.001) and percentage
IH area 38 vs 17% (p < 0.001), respectively.
t coverage, 6 months after zotarolimus-eluting stent implantation
ean stent area, NIH area (NIHA) and lumen area (LA) (mm2) in all
P1: proximal-medial; M: medial; D1: distal-medial; D2: distal). B.
gitudinal stent segments (bars), and neointimal hyperplasia (NIH)
ross sections and in ﬁve longitudinal stent segments.
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rFigure 4. Relationship between mean strut coverage thickness, n
tomography and stent length (A, B) and stent diameter (C, D), 6 mo
Guagliumi et al. reported a similar difference in the
ODESSA trial [20], in which 77 patients (189 stents) were ran-
domised and monitored by OCT 6 months after long-lesion
stenting requiring overlapping stents: mean percentage NIH
was 19.3% with SESs, 31.5% with PESs, 45.2% with ZESs and
57.8% with bare-metal stents.
The present mean 0.333mm strut coverage thickness
(to be multiplied by two to obtain the OCT diameter late-
loss value) agrees with the late-loss values reported in the
ENDEAVOR II and IV studies (0.61 and 0.67mm, respec-
tively [21]). It was noteworthy that coverage thickness was
independent of stent diameter or length (Fig. 4), mak-
ing percentage obstruction greater with small-diameter
stents (Fig. 4D); with a constant strut coverage thickness
of 0.333mm, obstruction with a 2.5mm diameter stent the-
oretically approximates 50%.
ZES strut coverage was virtually complete by 6 months. In
other series [18—20], as in the present, no thrombi were ever
reported and ZES strut coverage was almost total on OCT.
First-generation DES coverage was less at 6 or 9 months, with
8 to 12% of SES struts remaining non-covered [14,18,20],
and was still incomplete at 24 months (5% non-covered SES
struts) [22].
The originality of the present study lay in its analy-
sis of the spatial distribution of NIH at six months post
stenting. NIH proved homogeneous in terms of both cov-
erage thickness and non-covered strut ratio, longitudinally
and axially. There were no signiﬁcant differences between
the ﬁve longitudinal stent segments, while NIH variability
was very low on all slices. These data suggest that, in the
present series, the coronary response to zotarolimus was
homogeneous.
a
b
O
t
vimal hyperplasia (NIH) obstruction measured by optical coherence
after zotarolimus-eluting stent implantation (n = 42).
Non-uniform NIH was observed in previous intravascular
ltrasound studies of SESs, attributed by the authors to pos-
ible non-uniform stent distribution, stent under-expansion
23,24] or a heterogeneous local response to the drug [25].
In the present series, the homogeneous reaction may be
xplained by the non-occurrence of stent under-expansion
conﬁrmed by stent area measurement), lesion selection
or OCT feasibility, which excluded more complex plaques,
nd the absence of overlapping. The speciﬁc impact of
otarolimus or of the stent platform will need to be investi-
ated in larger-scale, comparative studies.
Anatomopathology studies reported delayed endothe-
ialization after DES implantation. Post-mortem studies on
rst-generation DESs found NIH to be sometimes heteroge-
eous, with a converse relationship between non-covered
trut ratio and NIH thickness [11]. Finn et al. reported that
non-covered strut ratio of > 0.30 in a given cross sec-
ion increased the intrastent thrombosis risk ninefold. The
ost recent OCT studies have adopted this prognostic index
16,18]. We also found in the present series a relationship
etween NIH and non-covered strut ratio (Fig. 2).
Deﬁcient strut coverage on OCT can be considered to be
thrombosis risk marker. There is, however, a discrepancy
etween the rate of non-covered active stents at several
onths post implantation and the much lower rate of late
hrombosis. Such ‘‘vulnerable’’ stents may be at increased
isk of thrombosis in case of termination of or resistance to
ntiplatelet therapy. If a correlation could be demonstrated
etween OCT ﬁndings and large-scale clinical study results,
CT might be able to guide the duration of dual antiplatelet
herapy, comparing theoretical late thrombosis risk for the
arious kinds of stent.
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tudy limitations
here are some limitations to this study. The series com-
rised only 25 patients and analysis concerned only 42
tents. Lesions were selected for OCT (M2 version, LightLab
maging) feasibility. The most complex stenoses (bifur-
ations, overlapping, in tortuous or calciﬁed coronary
rteries) were excluded. Moreover, despite its good per-
ormance, OCT cannot be assimilated to in vivo histology.
ertain aspects of coverage may, in fact, be due to ﬁb-
in or microthrombus. Conversely, endothelialization may be
nderestimated on OCT, when thin and translucent.
onclusion
CT provides precise measurement of NIH volume and
tent—strut coverage. The present study found constant,
omogeneous NIH, 6 months after ZES implantation. The
ean strut coverage thickness of 333m did not lead to
igniﬁcant angiographic stenosis or recurrent angina, but
ould be harmful for the smallest stent diameters. On the
ther hand, ZES strut coverage at 6 months was almost
otal and homogeneous. The converse relationship between
ean strut coverage thickness and non-covered strut ratio
eported in anatomopathology was conﬁrmed on OCT. The
elevance of these ﬁndings to the issue of intrastent throm-
osis, especially on termination of antiplatelet biotherapy,
hould be investigated in larger-scale clinical studies.
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